journal article·2011-11-22

Reshaping the Future of Nanopharmaceuticals: Ad Iudicium

S. Moein Moghimi, Dan Peer, Robert Langer

ACS Nano· Volume 5· Issue 11
Publisher page

Abstract

We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoparticles: synthesis and applications · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre for Pharmaceutical Nanotechnology and Nanotoxicology, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark

Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, and the Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel

Department of Chemical Engineering, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

References (28)

Show source-provided references
1. Moghimi S. M. · FASEB J. · 2005 · 19 · 31110.1096/fj.04-2747rev ↗
2. Allen T. M. · Science · 2004 · 303 · 181810.1126/science.1095833 ↗
3. Peer D. · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
4. Burgess P. · Nat. Biotechnol. · 2010 · 28 · 126710.1038/nbt.1725 ↗
5. Peer D. · Science · 2008 · 319 · 62710.1126/science.1149859 ↗
6. 10.1016/j.copbio.2011.02.01210.1016/j.copbio.2011.02.012 ↗
7. Dhar S. · Proc. Natl. Acad. Sci. U.S.A. · 2008 · 105 · 1735610.1073/pnas.0809154105 ↗
8. Blackstone E. A. · Future Med. Chem. · 2010 · 2 · 164110.4155/fmc.10.248 ↗
9. Grabowski H. · Nat. Rev. Drug Discovery · 2008 · 7 · 47910.1038/nrd2532 ↗
10. Parmar H. C. · Pharm. Technol. Eur. · 2006
11. Nat. Rev. Drug Discovery · 2009 · 8 · 83710.1038/nrd3040 ↗
12. Akavia U. D. · Cell · 2010 · 143 · 100510.1016/j.cell.2010.11.013 ↗
13. Nature · 2004 · 428 · 239
14. Petros R. A. · Nat. Rev. Drug Discovery · 2010 · 9 · 61510.1038/nrd2591 ↗
15. Kolishetti N. · Proc. Natl. Acad. Sci. U.S.A. · 2010 · 107 · 1793910.1073/pnas.1011368107 ↗
16. Swertz M. A. · Nat. Rev. Genetics · 2007 · 8 · 23510.1038/nrg2048 ↗
17. Semple S. C. · Nat. Biotechnol. · 2010 · 28 · 17210.1038/nbt.1602 ↗
18. Whitehead K. A. · Nat. Rev. Drug Discovery · 2009 · 8 · 12910.1038/nrd2742 ↗
19. Pecot C. V. · Nat. Rev. Cancer · 2011 · 11 · 5910.1038/nrc2966 ↗
20. Akthar S. · J. Clin. Invest. · 2007 · 117 · 362310.1172/JCI33494 ↗
21. Kedmi R. · Biomaterials · 2010 · 31 · 686710.1016/j.biomaterials.2010.05.027 ↗
22. Moghimi S. M. · Mol. Ther. · 2005 · 11 · 99010.1016/j.ymthe.2005.02.010 ↗
23. Szebeni J. · J. Liposome Res. · 2009 · 19 · 8510.1080/08982100902792855 ↗
24. Dobrovolskaia M. A. · Nat. Nanotechnol. · 2007 · 2 · 46910.1038/nnano.2007.223 ↗
25. Moghimi S. M. · FASEB J. · 2006 · 20 · 259110.1096/fj.06-6186fje ↗
26. Hamad I. · ACS Nano · 2010 · 4 · 662910.1021/nn101990a ↗
27. Puzyn T. · Nat. Nanotechnol. · 2011 · 6 · 17510.1038/nnano.2011.10 ↗
28. 10.1146/annurev-pharmtox-010611-13462310.1146/annurev-pharmtox-010611-134623 ↗